PET Imaging of Dementia: Update 2022

Brian J. Burkett, Jeffrey C. Babcock, Val J. Lowe, Jonathan Graff-Radford, Rathan M. Subramaniam, Derek R. Johnson

Research output: Contribution to journalArticlepeer-review


PET imaging plays an essential role in achieving earlier and more specific diagnoses of dementia syndromes, important for clinical prognostication and optimal medical management. This has become especially vital with the recent development of pathology-specific disease-modifying therapy for Alzheimer disease, which will continue to evolve and require methods to select appropriate treatment candidates. Techniques that began as research tools such as amyloid and tau PET have now entered clinical use, making nuclear medicine physicians and radiologists essential members of the care team. This review discusses recent changes in the understanding of dementia and examines the roles of nuclear medicine imaging in clinical practice. Within this framework, multiple cases will be shown to illustrate a systematic approach of FDG PET interpretation and integration of PET imaging of specific molecular pathology including dopamine transporters, amyloid, and tau. The approach presented here incorporates contemporary understanding of both common and uncommon dementia syndromes, intended as an updated practical guide to assist with the sophisticated interpretation of nuclear medicine examinations in the context of this rapidly and continually developing area of imaging.

Original languageEnglish (US)
Pages (from-to)763-773
Number of pages11
JournalClinical nuclear medicine
Issue number9
StatePublished - Sep 1 2022


  • Alzheimer disease
  • PET
  • amyloid
  • dementia
  • tau

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'PET Imaging of Dementia: Update 2022'. Together they form a unique fingerprint.

Cite this